Abstract |
The APSI trial was a randomized placebo-controlled trial designed to assess the efficacy of 1 year of treatment by acebutolol in high-risk patients who had survived an acute myocardial infarction. At 1 year there was a statistically significant 48% relative reduction in total mortality (p = 0.019) in favor of acebutolol. In 1995 a long-term mortality survey was undertaken through an administrative inquiry and contacts with investigators. The vital status of 586 of the 607 (96.5%) patients enrolled was known at the cutoff date and all these patients were followed up for at least 5 years. During follow-up (in-trial and post-trial period), 74 deaths (24.8%) occurred in the acebutolol group and 96 (31.1%) in the placebo group (p = 0.10). No difference between the 2 groups was observed for the number of deaths that occurred after the end of the trial: 55 deaths (19.6%) among the 281 survivors in the acebutolol group and 59 deaths (21.7%) (p = 0.70) among the 272 survivors in the placebo group. The annual hazard rate (annual death rate), calculated year by year using the actuarial method, was significantly different (p < 0.01) only for the first year and was not significantly different thereafter. Thus, the initial benefit obtained in 1 year of treatment by acebutolol lasts for 5 years.
|
Authors | M Cucherat, J P Boissel, A Leizorovicz |
Journal | The American journal of cardiology
(Am J Cardiol)
Vol. 79
Issue 5
Pg. 587-9
(Mar 01 1997)
ISSN: 0002-9149 [Print] United States |
PMID | 9068513
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Adrenergic beta-Antagonists
- Placebos
- Acebutolol
|
Topics |
- Acebutolol
(therapeutic use)
- Actuarial Analysis
- Adrenergic beta-Antagonists
(therapeutic use)
- Cause of Death
- Follow-Up Studies
- France
(epidemiology)
- Humans
- Longitudinal Studies
- Myocardial Infarction
(drug therapy, mortality)
- Placebos
- Proportional Hazards Models
- Risk Factors
- Survival Rate
|